Author

Patrick M. Hagan

Sanford Burnham Prebys Medical Discovery Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Allison S. LimpertiD· 2 shared Dhanya R. Panickar· 2 shared Douglas J. SheffleriD· 2 shared Fabiana Izidro LayngiD· 2 shared Huiyu ReniD· 2 shared Lester J. LambertiD· 2 shared Maria Celeridad· 2 shared Nicholas D. P. CosfordiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Allison S. LimpertORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Synthesis and Characterization of ULK1/2 Kinase Inhibitors that Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer

Fabiana Izidro Layng, Huiyu Ren, Nicole A. Bakas, Dhanya R. Panickar, Lester J. Lambert, Maria Celeridad, Jiaqian Wu, Laurent J. S. De Backer, Preeti Chandrachud, Allison S. Limpert, Mitchell Vamos, A. Chaikuad, Betsaida Bibo‐Verdugo, Patrick M. Hagan, Sonja N. Brun, , Nicholas D. P. Cosford

The paper reports the design, synthesis, and characterization of new ULK1/2 inhibitors that inhibit autophagy and upregulate MHC I in NSCLC cells, supporting their potential as cancer therapeutics.

ACS Chemical Biology · Feb 12, 2026Peer-reviewedCancer Biology

ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers

Patrick M. Hagan, Huiyu Ren, Sonja N. Brun, Fabiana Izidro Layng, Dhanya R. Panickar, Lester J. Lambert, Maria Celeridad, Ranajit Das, Ling Li, Yijuan Zhang, Allison S. Limpert, Douglas J. Sheffler, Cosimo Commisso, Reuben J. Shaw, Nicholas D. P. Cosford

The paper identifies SBP-1750, a ULK inhibitor that degrades ATG13 and kills KRAS-mutant cancer cells, showing efficacy in vivo and immune enhancement.

bioRxiv · Oct 14, 2025 · PreprintCancer Biology